Why the study?
NOACs have not been tested in randomized trials conducted in patients with AF and malignant disease, despite increasing clinical use.
Are non-vitamin K antagonist oral anticoagulants (NOACs) effective and safe in cancer patients with atrial fibrillation?
Are non-vitamin K antagonist oral anticoagulants (NOACs) effective and safe in cancer patients with atrial fibrillation?
This review highlights the growing real-world evidence and expert consensus supporting the use of NOACs in the vulnerable population of cancer patients with atrial fibrillation.
May guide NOAC selection in cancer patients with AF; extends real-world evidence synthesis but leaves RCTs needed.
Non-vitamin K antagonist oral anticoagulants (NOACs), or direct oral anticoagulants have not been tested in randomized trials conducted in patients with atrial fibrillation (AF), who had malignant disease. However, their use in cancer patients increases and real-life evidence for their effectiveness and safety in this vulnerable subset of patients is growing. The challenges of the use of NOACs in cancer patients with AF and the current expert opinions on this subject have been summarized in this review article.
No takes yet. Share an insight, caveat, or question.
Anetta Undas (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: